ImmunityBio, Inc. (IBRX) stock analysis
IBRX · ImmunityBio, Inc.
Latest recorded price: USD 5.98
Sector and industry: Healthcare · Biotechnology
Fiscal 2025 figures: revenue growth 678.6%, free cash flow margin -272.6%. The model flags 2 risk signals for this company (1 high severity).